Genprex, Inc. Overview
Pro stress-test →Genprex, Inc. (NASDAQ: GNPX) is a clinical-stage gene therapy company developing therapies for patients with cancer and diabetes. The company focuses on administering disease-fighting genes to address large patient populations that have limited treatment options in oncology and metabolic disease.
Strategic Profile
Pro stress-test →Its oncology platform uses the systemic, non-viral Oncoprex® Delivery System, which encapsulates gene-expressing plasmids in lipid-based nanoparticles in a lipoplex form, administered intravenously to restore expression of tumor suppressor proteins in cancer cells. Each of Genprex's lung cancer clinical programs with Reqorsa has received FDA Fast Track Designation, and the SCLC program has received FDA Orphan Drug Designation.
Competitive Landscape
Pro stress-test →Genprex operates in the highly competitive gene therapy space targeting cancer and diabetes. Direct competitors include larger, better-funded players like Spark Therapeutics, Bluebird Bio, and Moderna in the gene therapy sector, as well as traditional oncology and diabetes treatment companies. Genprex's primary competitive advantage lies in its non-viral Oncoprex delivery platform and first-mover systemic gene therapy for cancer applications.
Industry Context
Genprex, Inc. operates in Biotechnology / Gene Therapy.
Key facts
Founded: 2009 · Headquarters: Austin, Texas · Employees: 15 · Revenue: $0 · Market cap: $4-5M